Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by GREGORY N FULLER and AMY B HEIMBERGER.
GREGORY N FULLER
Connection Strength
4.939
AMY B HEIMBERGER
  1. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res. 2008 Aug 15; 14(16):5166-72.
    View in: PubMed
    Score: 0.337
  2. Correction: Detecting the percent of peripheral blood mononuclear cells displaying p-STAT-3 in malignant glioma patients. J Transl Med. 2024 Mar 21; 22(1):296.
    View in: PubMed
    Score: 0.249
  3. A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma. CNS Oncol. 2022 06 01; 11(2):CNS87.
    View in: PubMed
    Score: 0.219
  4. A validated integrated clinical and molecular glioblastoma long-term survival-predictive nomogram. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdaa146.
    View in: PubMed
    Score: 0.197
  5. Profiling of patients with glioma reveals the dominant immunosuppressive axis is refractory to immune function restoration. JCI Insight. 2020 09 03; 5(17).
    View in: PubMed
    Score: 0.194
  6. Radiation with STAT3 Blockade Triggers Dendritic Cell-T cell Interactions in the Glioma Microenvironment and Therapeutic Efficacy. Clin Cancer Res. 2020 09 15; 26(18):4983-4994.
    View in: PubMed
    Score: 0.192
  7. Anti-PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells. Clin Cancer Res. 2020 09 01; 26(17):4699-4712.
    View in: PubMed
    Score: 0.192
  8. Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial. Clin Cancer Res. 2020 07 15; 26(14):3565-3577.
    View in: PubMed
    Score: 0.189
  9. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol. 2020 04 15; 22(4):539-549.
    View in: PubMed
    Score: 0.189
  10. Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target. J Clin Invest. 2019 01 02; 129(1):137-149.
    View in: PubMed
    Score: 0.172
  11. Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes. Oncoimmunology. 2018; 7(4):e1412909.
    View in: PubMed
    Score: 0.162
  12. Serum microRNA profiling in patients with glioblastoma: a survival analysis. Mol Cancer. 2017 03 11; 16(1):59.
    View in: PubMed
    Score: 0.153
  13. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro Oncol. 2016 10; 18(10):1357-66.
    View in: PubMed
    Score: 0.146
  14. Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI Insight. 2016; 1(2).
    View in: PubMed
    Score: 0.142
  15. Tipping a favorable CNS intratumoral immune response using immune stimulation combined with inhibition of tumor-mediated immune suppression. Oncoimmunology. 2016 May; 5(5):e1117739.
    View in: PubMed
    Score: 0.140
  16. MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints. Neuro Oncol. 2016 05; 18(5):639-48.
    View in: PubMed
    Score: 0.140
  17. PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol. 2016 Feb; 18(2):195-205.
    View in: PubMed
    Score: 0.137
  18. Therapeutic targets in subependymoma. J Neuroimmunol. 2014 Dec 15; 277(1-2):168-75.
    View in: PubMed
    Score: 0.130
  19. Effect of miR-142-3p on the M2 macrophage and therapeutic efficacy against murine glioblastoma. J Natl Cancer Inst. 2014 Aug; 106(8).
    View in: PubMed
    Score: 0.127
  20. miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. Cancer Res. 2013 Jul 01; 73(13):3913-26.
    View in: PubMed
    Score: 0.117
  21. Modulating antiangiogenic resistance by inhibiting the signal transducer and activator of transcription 3 pathway in glioblastoma. Oncotarget. 2012 Sep; 3(9):1036-48.
    View in: PubMed
    Score: 0.112
  22. The expression of p-STAT3 in stage IV melanoma: risk of CNS metastasis and survival. Oncotarget. 2012 Mar; 3(3):336-44.
    View in: PubMed
    Score: 0.108
  23. The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models. Int J Cancer. 2012 Jul 01; 131(1):8-17.
    View in: PubMed
    Score: 0.104
  24. Hypoxia potentiates glioma-mediated immunosuppression. PLoS One. 2011 Jan 20; 6(1):e16195.
    View in: PubMed
    Score: 0.100
  25. Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses. Clin Cancer Res. 2010 Dec 01; 16(23):5722-33.
    View in: PubMed
    Score: 0.098
  26. Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model. Clin Cancer Res. 2010 May 01; 16(9):2550-61.
    View in: PubMed
    Score: 0.095
  27. yuDetecting the percent of peripheral blood mononuclear cells displaying p-STAT-3 in malignant glioma patients. J Transl Med. 2009 Nov 09; 7:92.
    View in: PubMed
    Score: 0.092
  28. The role of tregs in human glioma patients and their inhibition with a novel STAT-3 inhibitor. Clin Neurosurg. 2009; 56:98-106.
    View in: PubMed
    Score: 0.087
  29. The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin Cancer Res. 2008 Dec 15; 14(24):8228-35.
    View in: PubMed
    Score: 0.086
  30. A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res. 2008 Sep 15; 14(18):5759-68.
    View in: PubMed
    Score: 0.085
  31. Cytochrome P450 1B1 expression in glial cell tumors: an immunotherapeutic target. Clin Cancer Res. 2007 Jun 15; 13(12):3559-67.
    View in: PubMed
    Score: 0.078
  32. Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas. Clin Cancer Res. 2005 Jan 01; 11(1):267-72.
    View in: PubMed
    Score: 0.066
  33. CXCR4 expression is associated with proneural-to-mesenchymal transition in glioblastoma. Int J Cancer. 2023 02 15; 152(4):713-724.
    View in: PubMed
    Score: 0.056
  34. Central nervous system immune interactome is a function of cancer lineage, tumor microenvironment, and STAT3 expression. JCI Insight. 2022 05 09; 7(9).
    View in: PubMed
    Score: 0.055
  35. The Role of Fibrinogen-Like Protein 2 on Immunosuppression and Malignant Progression in Glioma. J Natl Cancer Inst. 2019 03 01; 111(3):292-300.
    View in: PubMed
    Score: 0.044
  36. Qki deficiency maintains stemness of glioma stem cells in suboptimal environment by downregulating endolysosomal degradation. Nat Genet. 2017 01; 49(1):75-86.
    View in: PubMed
    Score: 0.037
  37. miR-182-5p Induced by STAT3 Activation Promotes Glioma Tumorigenesis. Cancer Res. 2016 07 15; 76(14):4293-304.
    View in: PubMed
    Score: 0.036
  38. Signal transducer and activator of transcription 5b drives malignant progression in a PDGFB-dependent proneural glioma model by suppressing apoptosis. Int J Cancer. 2015 May 01; 136(9):2047-54.
    View in: PubMed
    Score: 0.032
  39. Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma. Neuro Oncol. 2012 Sep; 14(9):1136-45.
    View in: PubMed
    Score: 0.028
  40. Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res. 2006 Jul 01; 12(13):3935-41.
    View in: PubMed
    Score: 0.018
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.